# Gamgee

Source: https://onco.cc/companies/gamgee/  
OnCo record `gamgee` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Gamgee sequences a dog's tumour and designs a personalised mRNA vaccine that teaches its immune system what to attack, and is running trials in Australia with the aim of improving the approach with every case.

## Summary

Gamgee began when its founder used AI and genomic analysis to design what is believed to be the first fully computationally designed mRNA cancer vaccine given to a dog, with scientists at UNSW; several tumours shrank. The company now runs an end-to-end platform for personalised neoantigen mRNA vaccines in dogs, from veterinary intake and tissue collection through sequencing, vaccine manufacture, treatment and response monitoring, with clinical trials in Australia. It is a veterinary business included for its comparative oncology value; human applications are not claimed.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- Tags: veterinary; comparative-oncology
- HQ: San Francisco, CA
- Type: biotech
- Website: https://gamgee.io

## Sources

- Y Combinator profile: https://www.ycombinator.com/companies/gamgee
- Official website: https://gamgee.io

## Connected records

- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Personalised neoantigen (mRNA) vaccines](https://onco.cc/technologies/neoantigen-mrna-vaccine/)
- companies: [Y Combinator](https://onco.cc/companies/y-combinator/)

---
JSON: https://onco.cc/api/v1/entities/gamgee.json